Press Releases Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm Other stock markets 04:29:34 08/05/2024 pm IST			5-day change	1st Jan Change
2.905 ^SEK	-2.35%		-0.17%	-62.08%

15/04	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
04/04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncopeptides publishes final outcome in the fully guaranteed rights issue	07/05	AQ
Annual General Meeting in Oncopeptides AB (publ)	29/04	AQ
Oncopeptides publishes the 2023 Annual Report	22/04	AQ
Oncopeptides publishes prospectus relating to the rights issue	17/04	AQ
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	15/04	AQ
Oncopeptides secures national reimbursement for Pepaxti in Spain	15/04	AQ
Oncopeptides announces final terms for the fully guaranteed rights issue	08/04	AQ
Oncopeptides releases first quarter 2024 sales	04/04	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27/03	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27/03	AQ
Extraordinary General Meeting in Oncopeptides AB (publ)	13/03	AQ
Oncopeptides : Oncopeptalks on the company's rights issue	13/03	PU
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	13/03	AQ
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval	08/03	AQ
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	04/03	AQ
Oncopeptides : to present at two investor events	04/03	PU
Oncopeptides AB - Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	01/03	AQ
Oncopeptides' : PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	01/03	PU
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	01/03	AQ
Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	29/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncopeptides AB

Equities

ONCO

SE0009414576

Press Releases

Filters